Efficacy and Safety Study of MC-1101 1% TID in the Treatment of Nonexudative Age-Related Macular Degeneration
Status:
Terminated
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
This is a Phase II/III vehicle controlled, double masked, single center study. A single eye
of 60 individuals with mild to moderate nonexudative Age-Related Macular Degeneration (AMD)
will be randomly assigned to receive either topical 1% MC-1101 or a vehicle control over 2
years. The study design will assess the efficacy, safety, and tolerability of MC-1101 for
these patients.
An analysis of the primary and secondary endpoints will be conducted when all subjects have
completed 12, 18 and 24 months.